In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax , two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting…
Med Lett Drugs Ther. 2009 Nov 2; 51(1324):88
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax , two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old. Hiberix can also be given to children 12-15 months old as a scheduled booster dose. 1 1. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:1008. Download: U.S. English
A new pentavalent vaccine ( Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis…
Med Lett Drugs Ther. 2003 May 12; 45(1156):37-8
A new pentavalent vaccine ( Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis (Infanrix) and hepatitis B (Engerix-B) , and a new inactivated polio component.
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their…
Med Lett Drugs Ther. 1991 Jan 25; 33(836):5-7
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their primary immunization schedule.
A new Haemophilus influenzae type b capsular polysaccharide vaccine conjugated with diphtheria toxoid ( ProHIBiT - Connaught) was recently marketed in the USA. It is being promoted as a replacement for older,…
Med Lett Drugs Ther. 1988 Apr 22; 30(764):47-8
A new Haemophilus influenzae type b capsular polysaccharide vaccine conjugated with diphtheria toxoid ( ProHIBiT - Connaught) was recently marketed in the USA. It is being promoted as a replacement for older, unconjugated H. influenzae vaccines ( b- Capsa I ; Hibimune ; HibVAX ) previously reviewed in The Medical Letter (Volume 27, page 61, 1985).